Shiv Telegram Media: Weight-loss Drug Use Could Boost US GDP by 1%
2 min read
According to a recent report from Reuters, the use of weight-loss drugs in the U.S. has the potential to significantly boost the country’s gross domestic product. In fact, experts predict that the market for weight-loss drugs could reach a staggering $100 billion a year by the end of the decade.
Leading the race in the weight-loss drugs market are GLP-1 agonists, including well-known brands like Ozempic and Mounjaro. These drugs have the potential to increase GDP by 1% if used by as many as 60 million consumers by 2028, according to estimates from Goldman Sachs. With just 30 million users, the drugs could still bolster the U.S. GDP by 0.4%.
While the potential economic benefits are clear, weight-loss drugs have faced criticism from the body-positivity movement. Despite this, healthcare innovation such as AI-powered drug discovery combined with GLP-1s could further raise the U.S. GDP by 1.3% in the coming years.
Research on weight-loss drugs is expanding beyond just weight loss, with studies now looking at potential benefits for conditions such as alcohol addiction and dementia. Popular drugs containing semaglutide and liraglutide have shown promising results, helping individuals lose more than 10% of their body weight.
As the demand for weight-loss drugs continues to grow, clinical trials are being set up to explore further benefits and potential uses of these medications. With the impact of weight-loss drugs on the economy and healthcare system becoming increasingly clear, it will be interesting to see how this market evolves in the years to come.
“Communicator. Award-winning creator. Certified twitter geek. Music ninja. General web evangelist.”
